Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 36Capecitabine 28Trastuzumab 23Paclitaxel 22Surveys and Questionnaires 20Cyclophosphamide 20Gemcitabine 18Docetaxel 18Carboplatin 15Nivolumab 14Methods 14Magnetic Resonance Spectroscopy 13Early Intervention, Educational 13Bevacizumab 13Interviews as Topic 12Blood Specimen Collection 12fludarabine 11Standard of Care 11Irinotecan 11olaparib 10durvalumab 10Specimen Handling 10Psychiatric Rehabilitation 10palbociclib 9aldesleukin 9Taxes 9Fulvestrant 9Fluorouracil 9Exercise 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Dihydrouracil Dehydrogenase (NADP) × Gastrointestinal × Clear all
NCT05266300 2022-11-01

Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.

University of Southern Denmark

Completed
722 enrolled
BreastGastrointestinal

Bile Duct Neoplasms, Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡